Safety and Effectiveness of IHAT in Iron Deficient Pre-menopausal Woman
Status:
Not yet recruiting
Trial end date:
2025-12-01
Target enrollment:
Participant gender:
Summary
This is a double blind, randomised, placebo-controlled trial to evaluate orally-dosed IHAT
(iron hydroxide adipate tartrate) at 2 different doses compared to placebo for increasing
serum ferritin levels in iron-deficient but otherwise healthy premenopausal women over 12
weeks.